Open access · US-GOV via ClinicalTrials.gov Clinical trial

GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients

Authors not listed

McGill University Health Centre/Research Institute of the McGill University Health Centre · 2021

Dysbiosis Telomerase activation Human Randomized controlled trial

Abstract

In this trial, investigators will distribute educational brochures with information about the deprescription of gabapentinoids (gabapentin and pregabalin) to inpatients in five medical wards spread across two tertiary-care hospitals in Montréal, Canada. This intervention will be supplemented by a brief information session for medical staff on the wards. This study aims to evaluate the effectiveness of this combined intervention on increasing gabapentinoid deprescription rates among study participants compared to control following hospital discharge.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source: ClinicalTrials.gov
Canonical: link ↗
Fetched: 2026-10-22 MST

Cite this

APA

Anonymous. (2021). GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients. <em>McGill University Health Centre/Research Institute of the McGill University Health Centre</em>. https://clinicaltrials.gov/study/NCT04855578

Vancouver

Anonymous. GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients. McGill University Health Centre/Research Institute of the McGill University Health Centre. 2021.

BibTeX

@misc{anon2021GABAWH, title = {GABA-WHY Study: Deprescription of Gabapentinoids in Medical Inpatients}, author = {Anonymous}, journal = {McGill University Health Centre/Research Institute of the McGill University Health Centre}, year = {2021}, }